[1] Gustot T,Jalan R. Acute-on-chronic liver failure in patients with alcohol-related liver disease. J Hepatol,2019,70(2):319-327. [2] 陈韬,宁琴.亚太肝病学会慢加急性(亚急性)肝衰竭专家共识2019年更新解读.中华传染病杂志,2019,37(9):561-564. [3] Yao J, Li S, Zhou L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. J Clin Apher, 2019,34(4):392-398. [4] Fernández-Zarzoso M, Gómez-Seguí I, de la Rubia J. Therapeutic plasma exchange: Review of current indications. Transfus Apher Sci, 2019,58(3):247-253. [5] Clark WF, Huang SS. Introduction to therapeutic plasma exchange. Transfus Apher Sci, 2019,58(3):228-229. [6] Yuan L, Zeng BM, Liu LL, et al. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol, 2019,21(19):2327-2337. [7] 孔令希,邱峰,王红梅,等. 血浆置换联合双重血浆吸附治疗早、中、晚期肝衰竭的经济学评价.中华肝脏病杂志, 2020,28(5):434-440. [8] 中华医学会感染病学分会肝衰竭与人工肝学组;中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2019,22(2):164-171. [9] Sarin SK, Choudhury A, Sharma MK, et al. APASL ACLF Research Consortium (AARC) for APASL ACLF Working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.Hepatol Int,2019,13(4):353-390. [10] Stravitz RT, Lee WM. Acute liver failure. Lancet,2019,7(10):869-881. [11] 吴道诩,贾晓玉,谭颖,等. 局部枸橼酸钠抗凝在单重血浆置换中的临床应用. 中华肾脏病杂志,2020,36(11):866-869. [12] Tan EX, Wang MX, Pang J, Lee GH. Plasma exchange in patients with acute and acute-on-chronic liver failure: A systematic review. World J Gastroenterol, 2020,14(2):219-245. [13] 李永超,任红军,刘磊,等. 双重血浆吸附联合血浆置换治疗HBV-ACLF患者临床疗效研究. 实用肝脏病杂志,2020,23(2):90-93. [14] 应高翔,杨英,吴凤天,等. ACLF患者并发感染的特点及对诊断的影响. 中华临床感染病杂志, 2020,13(2):140-148. [15] Soundararajan R, Wang G, Petkova A, et al. Hyaluronidase coated molecular envelope technology nanoparticles enhance drug absorption via the subcutaneous route. Mol Pharm, 2020,17(7):2599-2611. [16] Patriquin CJ, Pavenski K. Plasma exchange in TTP: to taper or not to taper. Transfusion,2020,60(8):1647-1648. [17] 张国民,韩智炜,牛兴杰,等. PCT、IL-6、CD14、CD64及TNF-α表达对肝衰竭合并医院感染患者预后的影响. 中华医院感染学杂志, 2019,29(16):2450-2453. [18] 彭思璐,刘冰,孙宏,等. HBV相关ACLF患者预后及其影响因素分析. 实用肝脏病杂志, 2019,22(4):545-548. [19] Garraud O. Therapeutic plasma exchange, 2019 and beyond. Transfus Apher Sci, 2019,58(3):226-227. [20] Fernández-Zarzoso M, Gómez-Seguí I, de la Rubia J. Therapeutic plasma exchange: review of current indications. Transfus Apher Sci, 2019,58(3):247-253. [21] Saheb S, Gallo A. Urgent therapeutic plasma exchange. Transfus Apher Sci, 2020,59(6):102-104. [22] Tan EX, Wang MX, Pang J,et al.Plasma exchange in patients with acute and acute-on-chronic liver failure: A systematic review. World J Gastroenterol,2020,14(2):219-245. [23] Alamartine E, Maillard N. Therapeutic plasma exchange in nephrology. Where it applies? Transfus Apher Sci, 2019,58(3):262-265. [24] Garraud O, Coppo P. Types of fresh plasma with focus on therapeutic plasma exchange. Transfus Apher Sci, 2019,58(3):258-261. [25] 闫国胜,李丽丽,姜少利,等. 不同吸附剂在双重血浆分子吸附系统治疗肝衰竭中的临床研究.中华肝脏病杂志,2019,27(1):51-55. |